Short answer
Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Section 2.02 text contains only incorporation-by-reference and liability disclaimers.
Relay Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Section 2.02 text contains only incorporation-by-reference and liability disclaimers
- No earnings figures, reporting period, or operating-performance data included
Item EX-99.1 · Exhibit EX-99.1
- FDA Breakthrough Therapy designation for zovegalisib plus fulvestrant strengthens regulatory support in 2L PIK3CA-mutant breast cancer
- 11.1-month median PFS and 44% ORR support zovegalisib’s differentiated efficacy case, though data remain clinical-stage
- Phase 3 frontline triplet trial expected early 2027, with Pfizer supplying atirmociclib and palbociclib while Relay retains global zovegalisib rights
- Cash, cash equivalents and investments reached $642.1 million, including $137.1 million from ATM offerings, funding operations into 2029
- Q1 net loss narrowed to $73.3 million from $77.1 million, while revenue declined to $3.0 million from $7.7 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Relay Therapeutics, Inc. 8-K filings
Get the next RLAY 8-K as it lands
Follow RLAY for push alerts, or ask the research agent what this filing means.